4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol has been researched along with haloperidol in 61 studies
| Studies (4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol) | Trials (4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol) | Recent Studies (post-2010) (4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol) | Studies (haloperidol) | Trials (haloperidol) | Recent Studies (post-2010) (haloperidol) |
|---|---|---|---|---|---|
| 70 | 12 | 9 | 20,330 | 1,753 | 3,294 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (11.48) | 18.7374 |
| 1990's | 37 (60.66) | 18.2507 |
| 2000's | 8 (13.11) | 29.6817 |
| 2010's | 5 (8.20) | 24.3611 |
| 2020's | 4 (6.56) | 2.80 |
| Authors | Studies |
|---|---|
| Childers, SR; Hammond, PS; Huang, Y; Kuhner, RJ; Mach, RH; Whirrett, BR; Wu, L | 1 |
| Hammond, PS; Huang, Y; Mach, RH; Wu, L | 1 |
| Bernardini, R; Fiorito, J; Marrazzo, A; Pasquinucci, L; Prezzavento, O; Ronsisvalle, G; Ronsisvalle, S; Scoto, GM; Zappalà, L | 1 |
| Cacciatore, I; Cataldi, A; Di Giacomo, V; Di Stefano, A; Fiorito, J; Marinelli, L; Marrazzo, A; Pacella, S; Parenti, C; Rescifina, A; Sozio, P; Turkez, H | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Amata, E; Anfuso, CD; Arena, E; Caporarello, N; Drago, F; Fiorito, J; Giurdanella, G; Lupo, G; Marrazzo, A; Olivieri, M; Prezzavento, O; Rescifina, A; Salerno, L; Vinciguerra, S | 1 |
| Amata, E; Anfuso, CD; Barbaraci, C; Cacciatore, I; Dichiara, M; Giurdanella, G; Leotta, CG; Longo, A; Lupo, G; Marrazzo, A; Pasquinucci, L; Pitari, GM; Prezzavento, O; Turnaturi, R; Zuccarello, E | 1 |
| Amata, E; Artacho-Cordón, A; Barbaraci, C; Cobos, EJ; Dichiara, M; Gómez-Guzmán, M; González-Cano, R; Marrazzo, A; Pasquinucci, L; Rodríguez-Gómez, I; Santos-Caballero, M; Turnaturi, R | 1 |
| Casanova, MF; Jaskiw, GE; Kleinman, JE; Kolachana, B; Laruelle, M; Lipska, BK; Weinberger, DR | 1 |
| Gaertner, HJ; Mahal, A; Stevens, A | 1 |
| Bertilsson, L; Dahl, ML; Ekqvist, B; Llerena, A | 2 |
| Hasegawa, K; Hirayama, H; Matsuno, H; Nakashima, M; Sato, H; Uematsu, T | 1 |
| Gaertner, HJ; Mahal, A; Stevens, A; Stevens, I | 1 |
| Chang, WH | 1 |
| Dysken, MW; Holden, L; Johnson, SB; Kim, SW; Skare, S; Thomsyck, L; Vatassery, G | 1 |
| Cooper, TB; Czobor, P; Volavka, J | 1 |
| Chang, WH; Chen, H; Jann, MW; Lam, YW | 1 |
| Chang, WH; Chen, H; Chen, TY; Chien, CP; Davis, CM; Hwu, HG; Jann, MW; Lam, YW; Lin, HN; Lin, SK | 1 |
| Inaba, T; Noguchi, T; Shibasaki, M; Someya, T; Takahashi, S | 1 |
| Dysken, MW; Holden, L; Johnson, SB; Kuskowski, M; Ofstehage, J; Skare, S; Vatassery, G | 1 |
| Inaba, T; Kalow, W; Tyndale, RF | 1 |
| Chang, WH; Jann, MW; Lin, SK | 1 |
| Cahard, C; Conquy, T; Rop, PP; Viala, A | 1 |
| Cheung, SW; Inaba, T; Shibasaki, M; Someya, T; Takahashi, S; Tang, SW | 1 |
| Shibasaki, M; Someya, T; Takahashi, S | 2 |
| Egan, M; Freedman, R; Kirch, DG; Palmer, MR | 1 |
| Chang, WH; Tseng, YT; Wu, HS | 1 |
| Chang, WH; Chen, TY; Hu, WH; Lee, CF; Yeh, EK | 1 |
| Hawes, EM; Hubbard, JW; Korchinski, ED; McKay, G; Midha, KK | 1 |
| Browning, JL; Davis, CM; Harrington, CA | 1 |
| Costakos, DT; Kleinman, JE; Korpi, ER; Linnoila, M; Wyatt, RJ | 1 |
| Knorr, W; Meyer, FP; Neuhof, S; Ulrich, S | 1 |
| Eyles, DW; Pond, SM; Stedman, TJ | 1 |
| Chang, WH; Chien, CP; Jann, MW; Liu, HC; Shieh, YS | 1 |
| Aravagiri, M; Marder, SR; Marshall, BD; Van Putten, T | 1 |
| Bouhours, P; Elia, E; Erb, F; Jacquet, M; Leroux, JM; Levron, JC; Pommery, J; Sechter, D | 1 |
| Chang, WH; Chen, LC; Chien, CP; Hu, WH; Jann, MW; Juang, DJ; Lam, YF; Lin, SK; Yang, CH | 1 |
| Chang, WH; Chen, LC; Chien, CP; Hu, WH; Jann, MW; Juang, DJ; Lam, YW; Lin, SK; Yang, CH | 1 |
| Chang, WH; Chiang, TS; Chien, CP; Hu, WH; Jann, MW; Lin, HN | 1 |
| Castagnoli, N; Fukui, M; Idzu, T; Igarashi, K; Kasuya, F; Matsubara, K | 1 |
| Dupuy, JL; Hoja, H; Lachâtre, G; Lotfi, H; Marquet, P; Pénicaut, B; Verneuil, B | 1 |
| Carter, JG; Crabtree, BL; Jann, MW; Lam, YW; Pitts, WM | 1 |
| Chang, WH; Chang, YC; Hu, OY; Hu, WH; Jann, MW; Lane, HY; Lin, HN | 1 |
| Eyles, DW; McGrath, JJ; Pond, SM; Stedman, TJ | 1 |
| Belpaire, FM; De Vriendt, C; Pan, LP | 1 |
| Han, CS; Kim, SH; Lee, MS; You, YW | 1 |
| Braun, V; Meyer, FP; Neuhof, S; Ulrich, S | 1 |
| Belpaire, FM; Berlo, JA; De Schepper, N; Pan, L; Rosseel, MT; Vander Stichele, R | 1 |
| Belpaire, FM; Pan, L | 1 |
| Furukori, H; Inoue, Y; Kaneko, S; Kondo, T; Mihara, K; Nagashima, U; Ono, S; Otani, K; Suzuki, A; Yasui, N | 1 |
| Flockhart, DA; Kane, K; Shin, JG | 1 |
| Fujita, R; Furusawa, S; Ishikawa, M; Kataoka, Y; Miura, M; Sasaki, K; Takayanagi, M; Takayanagi, Y; Takeshita, M | 1 |
| Arinobu, T; Hattori, H; Ishii, A; Seno, H; Suzuki, O | 1 |
| Furukori, H; Inoue, Y; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Suzuki, A; Yasui-Furukori, N | 1 |
| Hamachi, C; Imamura, Y; Kishikawa, N; Kuroda, N; Nakashima, K; Ohba, Y; Tagawa, Y | 1 |
| Baeyens, JM; Cendán, CM; Cobos, EJ; Del Pozo, E; Entrena, JM; Nieto, FR | 1 |
| Fang, J; Song, J | 1 |
| Ishii, A; Natori, Y; Yamamoto, T; Yoshimoto, T | 1 |
| Chen, Z; Gao, RD; Gori, SS; LaPorte, HM; Luedtke, RR; Mach, RH; McInnis, T; Neisewander, JL; Rais, R; Siegler, MA; Singh, M; Slusher, BS; Taylor, M; Tsukamoto, T | 1 |
1 review(s) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and haloperidol
| Article | Year |
|---|---|
Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?
Topics: Animals; Haloperidol; Humans; Schizophrenia | 1992 |
11 trial(s) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and haloperidol
| Article | Year |
|---|---|
Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
Topics: Acute Disease; Adult; Drug Therapy, Combination; Female; Haloperidol; Humans; Lorazepam; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1992 |
Plasma drug level and clinical response.
Topics: Chronic Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1992 |
Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics.
Topics: Adult; Chromatography, Gas; Drug Monitoring; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1995 |
Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms.
Topics: Adolescent; Adult; Aged; Blood Proteins; Chronic Disease; Cytosol; Erythrocytes; Female; Haloperidol; Humans; Hydrogen-Ion Concentration; Ketone Oxidoreductases; Liver; Male; Microsomes, Liver; Middle Aged; Protein Binding; Schizophrenia; Stereoisomerism | 1994 |
Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Resistance; Haloperidol; Humans; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia | 1994 |
Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol.
Topics: Administration, Oral; Chromatography, Liquid; Delayed-Action Preparations; Drug Resistance; Electrochemistry; Haloperidol; Humans; Injections, Intramuscular; Schizophrenia | 1994 |
Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Orosomucoid; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1997 |
Chirality of reduced haloperidol in humans.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Haloperidol; Humans; Male; Middle Aged; Oxidation-Reduction; Stereoisomerism | 1998 |
Co-administration of sertraline and haloperidol.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Metabolic Clearance Rate; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Sertraline | 1998 |
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia | 1999 |
Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Topics: Adult; Aged; Antipsychotic Agents; Cyclizine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Histamine H1 Antagonists; Humans; Male; Middle Aged; Promethazine; Schizophrenia | 2003 |
49 other study(ies) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and haloperidol
| Article | Year |
|---|---|
Synthesis and quantitative structure-activity relationships of N-(1-benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective sigma1 receptor ligands.
Topics: Acetamides; Acetanilides; Animals; Benzamides; Brain; Guinea Pigs; Ligands; Liver; Male; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, sigma; Structure-Activity Relationship | 1998 |
Synthesis and structure-activity relationships of N-(1-benzylpiperidin-4-yl)arylacetamide analogues as potent sigma1 receptor ligands.
Topics: Acetamides; Animals; Brain; Fluorine; Guinea Pigs; In Vitro Techniques; Iodine; Ligands; Liver; Models, Molecular; Piperidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Structure-Activity Relationship | 2001 |
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Guinea Pigs; Haloperidol; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Phenylbutyrates; Prostatic Neoplasms; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, sigma | 2011 |
Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioma; Haloperidol; Molecular Structure; Prodrugs; Rats; Structure-Activity Relationship; Tumor Cells, Cultured | 2015 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells.
Topics: Angiogenesis Inhibitors; Cell Survival; Dose-Response Relationship, Drug; Endothelial Cells; Haloperidol; Humans; Microvessels; Molecular Structure; Neovascularization, Physiologic; Retina; Structure-Activity Relationship; Valproic Acid | 2016 |
Haloperidol Metabolite II Valproate Ester (
Topics: Angiogenesis Inhibitors; Butyrophenones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Melanoma; Pentanoic Acids; Piperidines; Prodrugs; Stereoisomerism; Uveal Neoplasms; Valerates | 2021 |
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation.
Topics: Animals; Guinea Pigs; Hydrogen; Hydrogen Sulfide; Ligands; Male; Morpholines; Pain; Piperazines; Rats, Sprague-Dawley; Receptors, sigma; Sigma-1 Receptor | 2022 |
D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment.
Topics: Animals; Cerebellum; Chromatography, High Pressure Liquid; Corpus Striatum; Haloperidol; Male; Motor Activity; Nucleus Accumbens; Radioligand Assay; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Time Factors | 1992 |
Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
Topics: Adult; Chromatography, High Pressure Liquid; Haloperidol; Humans; Middle Aged; Psychiatric Status Rating Scales; Regression Analysis; Schizophrenia; Schizophrenic Psychology | 1992 |
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
Topics: Chromatography, High Pressure Liquid; Debrisoquin; Haloperidol; Humans; Hydroxylation; Oxidation-Reduction; Phenotype | 1992 |
Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Female; Hair; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1992 |
Genetic factors in the metabolism of haloperidol.
Topics: Debrisoquin; Half-Life; Haloperidol; Humans; Hydroxylation; Phenotype | 1992 |
Haloperidol decanoate pharmacokinetics in red blood cells and plasma.
Topics: Adult; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Erythrocytes; Female; Haloperidol; Humans; Male; Metabolic Clearance Rate; Psychiatric Status Rating Scales; Psychotic Disorders | 1992 |
Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.
Topics: Administration, Oral; Adult; Biological Availability; China; Chromatography, High Pressure Liquid; Half-Life; Haloperidol; Humans; Injections, Intravenous; Male; Middle Aged; Models, Biological; Schizophrenia | 1992 |
Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations.
Topics: Black or African American; Black People; China; Chromatography, Liquid; Ethnicity; Haloperidol; Hispanic or Latino; Humans; Psychiatric Status Rating Scales; Radioimmunoassay; Schizophrenia; United States; White People | 1992 |
Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Chromatography, High Pressure Liquid; Erythrocytes; Female; Glucuronates; Haloperidol; Humans; Male; Mental Disorders; Middle Aged; Oxidation-Reduction | 1992 |
Haloperidol and reduced haloperidol in saliva and blood.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Erythrocytes; Female; Haloperidol; Humans; Male; Mental Disorders; Middle Aged; Parotid Gland; Saliva | 1992 |
Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Haloperidol; Humans; In Vitro Techniques; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Quinidine; Quinine | 1991 |
Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
Topics: Adult; Animals; Biotransformation; Corpus Striatum; Dose-Response Relationship, Drug; Guinea Pigs; Haloperidol; Humans; Male; Middle Aged; Schizophrenia; Schizophrenic Psychology | 1991 |
High-performance liquid chromatographic analysis of haloperidol and hydroxyhaloperidol in plasma after solid-phase extraction.
Topics: Chromatography, High Pressure Liquid; Haloperidol; Humans; Quality Control | 1990 |
Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Japan; Male; Mental Disorders; Middle Aged | 1990 |
[The plasma levels of haloperidol and reduced haloperidol in Japanese psychiatric patients].
Topics: Adolescent; Adult; Aged; Asian People; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Japan; Male; Mental Disorders; Middle Aged | 1989 |
Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brain.
Topics: Animals; Antipsychotic Agents; Brain; Catecholamines; Dopamine Antagonists; Haloperidol; Norepinephrine; Phencyclidine; Rats; Rats, Inbred Strains; Synaptic Transmission | 1985 |
Reduced haloperidol and haloperidol: effects on homovanillic acid in caudate and prefrontal cortex.
Topics: Animals; Caudate Nucleus; Dose-Response Relationship, Drug; Frontal Lobe; Haloperidol; Homovanillic Acid; Male; Rats; Rats, Inbred Strains | 1987 |
Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.
Topics: China; Ethnicity; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1987 |
Interconversion between haloperidol and reduced haloperidol in humans.
Topics: Haloperidol; Humans | 1987 |
Quantification of reduced haloperidol and haloperidol by radioimmunoassay.
Topics: Chromatography, Liquid; Cross Reactions; Haloperidol; Humans; Radioimmunoassay; Schizophrenia | 1985 |
Reduced haloperidol in the post-mortem brains of haloperidol-treated patients.
Topics: Adult; Animals; Brain Chemistry; Cerebellum; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Corpus Striatum; Female; Haloperidol; Humans; Liver; Male; Middle Aged; Occipital Lobe; Rats; Rats, Inbred Strains; Schizophrenia | 1984 |
Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia.
Topics: Adult; Chromatography, High Pressure Liquid; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia, Paranoid; Schizophrenic Psychology; Spectrophotometry, Ultraviolet | 1994 |
Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
Topics: Administration, Oral; Adult; Chromatography, High Pressure Liquid; Female; Haloperidol; Humans; Male; Middle Aged; Regression Analysis; Schizophrenia | 1993 |
Relation of plasma and red blood cells reduced haloperidol concentrations to haloperidol reductase activity assayed in red blood cells in psychiatric population.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Erythrocytes; Female; Haloperidol; Humans; Japan; Male; Middle Aged; Psychotic Disorders | 1993 |
Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
Topics: Adult; Female; Half-Life; Haloperidol; Humans; Injections, Intramuscular; Male; Metabolic Clearance Rate; Middle Aged; Schizophrenia; Schizophrenic Psychology; Substance Withdrawal Syndrome | 1993 |
Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Dementia; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Metabolic Clearance Rate; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1996 |
Effect of a pyridinium metabolite derived from haloperidol on the activities of striatal tyrosine hydroxylase in freely moving rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Dihydroxyphenylalanine; Dopamine Agents; Enzyme Inhibitors; Haloperidol; Hydrazines; Hydroxyindoleacetic Acid; Male; Microdialysis; Neostriatum; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 1996 |
Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization.
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Electrochemistry; Haloperidol; Humans; Mass Spectrometry; Reproducibility of Results | 1997 |
Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Metabolic Clearance Rate; Middle Aged; Schizophrenia; Sex Factors | 1997 |
In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol.
Topics: Adolescent; Adult; Aged; Child; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dealkylation; Haloperidol; Humans; Isoenzymes; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases; Oxidation-Reduction; Piperidines | 1998 |
Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.
Topics: Adult; Aged; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Enzyme Induction; Enzyme Inhibitors; Genotype; Haloperidol; Humans; Inpatients; Middle Aged; Polymorphism, Genetic; Polypharmacy; Schizophrenia; Smoking | 1999 |
In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
Topics: Biotransformation; Child; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dopamine Antagonists; Enzyme Inhibitors; Haloperidol; Humans; Isoenzymes; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases; Oxidation-Reduction; Theophylline | 1999 |
Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Topics: Alleles; Antipsychotic Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Enzyme Induction; Female; Genotype; Haloperidol; Humans; Male; Middle Aged; Point Mutation; Polymorphism, Genetic; Schizophrenia; Smoking | 2000 |
Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.
Topics: Binding, Competitive; Biomarkers; Cytochrome P-450 CYP2D6 Inhibitors; Dextrorphan; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Haloperidol; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Phenols; Propanols; Stereoisomerism | 2001 |
Reversal of vinblastine resistance in human leukemic cells by haloperidol and dihydrohaloperidol.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Dihydropyridines; Drug Resistance, Neoplasm; Drug Synergism; Haloperidol; Humans; Leukemia; Photoaffinity Labels; Tumor Cells, Cultured; Vinblastine | 2001 |
Comparison of SSI with APCI as an interface of HPLC-mass spectrometry for analysis of a drug and its metabolites.
Topics: Antipsychotic Agents; Biotransformation; Chromatography, High Pressure Liquid; Haloperidol; Humans; Mass Spectrometry; Pharmaceutical Preparations; Piperidines; Ultrasonics | 2002 |
Determination of haloperidol and reduced haloperidol in human serum by liquid chromatography after fluorescence labeling based on the Suzuki coupling reaction.
Topics: Boron Compounds; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Fluorescence; Haloperidol; Humans; Male; Molecular Structure; Oxidation-Reduction; Reference Values; Reproducibility of Results; Schizophrenia; Sensitivity and Specificity | 2006 |
Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors.
Topics: Analysis of Variance; Animals; Brain; Capsaicin; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Hyperalgesia; Mice; Morpholines; Motor Activity; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Pentazocine; Physical Stimulation; Protein Binding; Radioligand Assay; Reaction Time; Receptors, sigma; Rotarod Performance Test; Sigma-1 Receptor; Tritium | 2009 |
In vitro characterization of the oxidation of a pyridinium metabolite of haloperidol by human placenta: the effect of smoking.
Topics: Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP3A; Female; Haloperidol; Humans; Microsomes; Microsomes, Liver; Oxidation-Reduction; Placenta; Pregnancy; Pyridinium Compounds; Smoking | 2012 |
Identification and quantification of diphenhydramine, haloperidol, and its metabolite, reduced haloperidol in a saponified brain specimen that was immersed in the sea water for more than 10 years.
Topics: Brain; Diphenhydramine; Haloperidol; Humans; Seawater; Tandem Mass Spectrometry | 2023 |
Synthesis and Pharmacological Characterization of a Difluorinated Analogue of Reduced Haloperidol as a Sigma-1 Receptor Ligand.
Topics: Animals; Brain-Derived Neurotrophic Factor; Haloperidol; Ligands; Mice; Receptors, sigma; Sigma-1 Receptor | 2023 |